Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.
João M Fernandes NetoErnest NadalEvert BosdrieszSalo N OoftLourdes FarreChelsea M McLeanSjoerd KlarenbeekAnouk JurgensHannes HagenLiqin WangEnriqueta FelipAlex Martinez-MartiAugust VidalEmile E VoestLodewyk F A WesselsOlaf van TellingenAlberto VillanuevaRené BernardsPublished in: Nature communications (2020)
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy.
Keyphrases
- small cell lung cancer
- low dose
- epidermal growth factor receptor
- signaling pathway
- tyrosine kinase
- pi k akt
- squamous cell carcinoma
- cell proliferation
- oxidative stress
- stem cells
- drug delivery
- advanced non small cell lung cancer
- high dose
- brain metastases
- papillary thyroid
- cell death
- electronic health record
- emergency department
- big data
- cell cycle arrest
- replacement therapy
- cell therapy
- smoking cessation